Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking.

Next Previous
Trial Profile

An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varenicline (Primary)
  • Indications Attention-deficit hyperactivity disorder; Smoking withdrawal
  • Focus Therapeutic Use

Most Recent Events

  • 11 May 2010 Actual patient number (2) added as reported by ClinicalTrials.gov.
  • 11 May 2010 Planned end date changed from 1 Apr 2012 to 1 May 2010 as reported by ClinicalTrials.gov.
  • 11 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top